Korro Bio, Inc.
KRRONASDAQHealthcare● Active
$10.59
$-0.13(-1.21%)
Market Cap$105406157
P/E Ratio—
52W High$55.89
52W Low$5.204
Korro Bio, Inc. (KRRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KRRO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.69
Est. -$1.60 · -5.6%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
KRRO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$1.31 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.60 | -$1.69 | -5.6% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$1.93 | -$5.32 | -175.7% | $0.00B | $0.00B | +85.7% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$2.61 | -$1.92 | +26.4% | $0.00B | $0.00B | +156.5% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$2.54 | -$2.74 | -7.9% | $0.00B | $0.00B | +355.1% |
| ▲ Q2 FY2025 | May 7, 2025 | -$2.60 | -$2.49 | +4.2% | $0.00B | $0.00B | +497.3% |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$2.33 | -$2.26 | +3.0% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$2.55 | -$2.26 | +11.4% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$1.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.69
EPS Est.
-$1.60
EPS Surpr.
-5.6%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$5.32
EPS Est.
-$1.93
EPS Surpr.
-175.7%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$1.92
EPS Est.
-$2.61
EPS Surpr.
+26.4%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$2.74
EPS Est.
-$2.54
EPS Surpr.
-7.9%
Revenue
$0.00B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$2.49
EPS Est.
-$2.60
EPS Surpr.
+4.2%
Revenue
$0.00B
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$2.26
EPS Est.
-$2.33
EPS Surpr.
+3.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$2.26
EPS Est.
-$2.55
EPS Surpr.
+11.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.50 | $-1.50 | $-1.50 | 2 |
| Q3 FY2027 | $-1.47 | $-1.47 | $-1.47 | 2 |
| Q2 FY2027 | $-1.44 | $-1.44 | $-1.44 | 2 |
| Q1 FY2027 | $-1.41 | $-1.41 | $-1.41 | 3 |
| Q4 FY2026 | $-1.30 | $-1.30 | $-1.30 | 3 |
| Q3 FY2026 | $-1.59 | $-1.26 | $-0.60 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -5.6% | $13.34 | $12.89 | -3.37% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -175.7% | $11.76 | $11.50 | -2.21% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +26.4% | $32.80 | $31.42 | -4.21% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -7.9% | $15.05 | $15.99 | +6.25% |
| ▲ Q2 FY2025 | May 7, 2025 | +4.2% | $14.80 | $13.93 | -5.88% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +3.0% | $25.06 | $24.17 | -3.55% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +11.4% | $73.50 | $65.14 | -11.37% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -1.3% | $35.97 | $36.36 | +1.08% |
Q2 FY2026-3.37%
Report Date
May 7, 2026
EPS Beat/Miss
-5.6%
Price Before
$13.34
Price After
$12.89
Q1 FY2026-2.21%
Report Date
Mar 12, 2026
EPS Beat/Miss
-175.7%
Price Before
$11.76
Price After
$11.50
Q4 FY2025-4.21%
Report Date
Nov 12, 2025
EPS Beat/Miss
+26.4%
Price Before
$32.80
Price After
$31.42
Q3 FY2025+6.25%
Report Date
Aug 12, 2025
EPS Beat/Miss
-7.9%
Price Before
$15.05
Price After
$15.99
Q2 FY2025-5.88%
Report Date
May 7, 2025
EPS Beat/Miss
+4.2%
Price Before
$14.80
Price After
$13.93
Q1 FY2025-3.55%
Report Date
Mar 18, 2025
EPS Beat/Miss
+3.0%
Price Before
$25.06
Price After
$24.17
Q4 FY2024-11.37%
Report Date
Nov 12, 2024
EPS Beat/Miss
+11.4%
Price Before
$73.50
Price After
$65.14
Q3 FY2024+1.08%
Report Date
Aug 13, 2024
EPS Beat/Miss
-1.3%
Price Before
$35.97
Price After
$36.36
Avg Beat Reaction-6.25%
Avg Miss Reaction+0.44%
Beat Rate4 / 8 quarters
Largest Move-11.37% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KRRO ends December
Korro Bio, Inc. (KRRO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.69 — missing the analyst consensus of $-1.60 by -5.6%. The next KRRO earnings date is expected around September 1, 2026.
Each quarter, investors track KRRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KRRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KRRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KRRO earnings · 5 questionsKorro Bio, Inc.'s next earnings report is expected around September 1, 2026. KRRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KRRO historically reports after market close (AMC).
KRRO earnings datewhen is KRRO earningsKRRO next earnings datewhen does KRRO report earningsKRRO earnings calendar
▸ Source: FMP · Korro Bio, Inc. SEC filings · US GAAP · Korro Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026